Literature DB >> 25898960

CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment.

Giulio Metro1, Gianluigi Lunardi2, Piero Floridi3, Jennifer P Pascali4, Luca Marcomigni5, Rita Chiari5, Vienna Ludovini5, Lucio Crinò5, Stefania Gori2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25898960     DOI： 10.1097/JTO.0000000000000468

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  40 in total

1.  ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.

Authors:  Malinda Itchins; Brandon Lau; Amanda L Hudson; Helen Westman; Cathy Yi Xia; Sarah A Hayes; Viive M Howell; Michael Rodriguez; Wendy A Cooper; Heng Wei; Michael Buckland; Bob T Li; Mark Li; Vivek Rathi; Stephen B Fox; Anthony J Gill; Stephen J Clarke; Michael J Boyer; Nick Pavlakis
Journal:  Oncologist       Date:  2020-07-02

Review 2.  Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.

Authors:  Panagiota Economopoulou; Giannis Mountzios
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 3.  ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.

Authors:  Ivana Sullivan; David Planchard
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

Review 4.  Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

Authors:  Francesco Facchinetti; Marcello Tiseo; Massimo Di Maio; Paolo Graziano; Emilio Bria; Giulio Rossi; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2016-06

5.  Ceritinib in second and further lines of therapy in advanced ALK mutant adenocarcinoma.

Authors:  György Losonczy
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

6.  Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.

Authors:  Giulio Metro; Gianluigi Lunardi; Chiara Bennati; Pietro Chiarini; Isabella Sperduti; Biagio Ricciuti; Luca Marcomigni; Cinzia Costa; Lucio Crinò; Piero Floridi; Stefania Gori; Rita Chiari
Journal:  J Neurooncol       Date:  2016-06-20       Impact factor: 4.130

7.  Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.

Authors:  Alberto Broniscer; Sujuan Jia; Belinda Mandrell; Dima Hamideh; Jie Huang; Arzu Onar-Thomas; Amar Gajjar; Susana C Raimondi; Ruth G Tatevossian; Clinton F Stewart
Journal:  Pediatr Blood Cancer       Date:  2018-03-07       Impact factor: 3.167

Review 8.  New generation anaplastic lymphoma kinase inhibitors.

Authors:  Angelo Delmonte; Marco Angelo Burgio; Alberto Verlicchi; Giuseppe Bronte; Paola Cravero; Paola Ulivi; Giovanni Martinelli; Lucio Crinò
Journal:  Transl Lung Cancer Res       Date:  2019-11

Review 9.  Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer.

Authors:  Nam Bui; Brian Woodward; Anna Johnson; Hatim Husain
Journal:  Curr Treat Options Oncol       Date:  2016-05

10.  A real-world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer.

Authors:  Ying Jin; Yamei Chen; Xinmin Yu; Xun Shi
Journal:  Oncol Lett       Date:  2018-04-05       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.